Outcomes study of CETP-inhibitor continues as planned

News - Nov. 16, 2015

The Data Monitoring Committee (DMC) of the REVEAL outcomes study for anacetrapib has completed its planned review of unblinded study data and recommended the study continue with no changes. The DMC reviewed safety and efficacy data from the study, which included an assessment of futility. Merck, the developer of anacetrapib, remains blinded to the actual results of this analysis and to other REVEAL safety and efficacy data.

REVEAL is a 30,000 patient, event-driven study sponsored by Oxford University, which is projected to conclude in early 2017. The REVEAL Steering Committee and Merck will continue to monitor the progress of the study. No additional interim efficacy analyses are planned.

Press release Merck November 13, 2015

Facebook Comments


We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free